Table 1 Study characteristics of randomized controlled trials of progesterone for maintenance tocolysis
Study | Year | Country | Number of Subjects | Study Population | Treatment/controls |
|---|---|---|---|---|---|
Areia [22] | 2013 | Portugal | 52 | 24–34 weeks gestation cervical length ≤ 25 mm after tocolysis with antosiban. | Progesterone 200 mg vaginally/No treatment. |
Borna [21] | 2008 | Iran | 70 | 24–34 weeks gestation after tocolysis with MgSO4, cervical dilation ≤2 cm. | Progesterone 400 mg vaginally/No treatment. |
Choudhary [13] | 2014 | India | 90 | 24–34 weeks gestation after tocolysis with nifedipine, cervical dilation >1 cm. | Progesterone 200 mg orally/Placebo |
Facchinetti [15] | 2007 | Italy | 60 | 25–34 weeks gestation after tocolysis with antosiban. | 17-hydroxyprogesterone caporate 341 mg IM q 4 days/ No treatment |
Kamat [20] | 2014 | India | 110 | <37 weeks gestation, after tocolysis with nifedipine. | Progesterone 400 mg vaginally/nifedipine 20 mg q8h. |
Lotfalizadeh [24] | 2013 | Iran | 110 | 26–36 weeks gestation, after tocolysis with nifedipine or MgSO4 | Progesterone 400 mg vaginally, or 17-hydroxyprogesterone caporate 250 mg IM/No treatment. |
Noblot [12] | 1991 | France | 44 | <37 weeks gestation, regular contractions, tocolysis with ritodrine | Progesterone 400 mg orally, started before cessation of contractions/Placebo. |
Palacio [19] | 2013 | Spain | 265 | 24–34 weeks gestation, cervical length ≤ 25 mm. Arrested preterm labour, tocolytic not specified | Progesterone 200 mg vaginally/Placebo. |
Rozenberg [14] | 2012 | France | 188 | 24–31 weeks gestation and cervical length < 25 mm after tocolysis | 17-hydroxyprogesterone caporate 500 mg biweekly/No treatment. |
Sharami [18] | 2010 | Iran | 173 | 28–36 weeks gestation, tocolysis with MgS04 | Progesterone 200 mg vaginally/Placebo. |
de Tejada | 2015 | Switzerland and Argentina | 384 | 24–33 weeks gestation, tocolysis with β-mimetics, antosiban, or calcium channel blockers. | Progesterone 200 mg vaginally/Placebo. |
Briery [16] | 2014 | USA | 45 | 20–30 weeks gestation, tocolysis with NSAIDS, nifedipine or MgSO4 | 17-hydroxyprogesterone caporate 250 mg IM weekly/ Placebo |
Gargari [23] | 2012 | Iran | 110 | 24–33 weeks gestation, tocolysis with MgSO4 | Progesterone 400 mg vaginally/No treatment |
Wood | 2017 | Canada | 41 | 23–33 weeks gestation, after tocolysis with NSAIDS or nifedipine or no tocolysis and positive vaginal fetal fibronectin | Progesterone 200 mg vaginally/Placebo. |